Reversing multidrug resistance in breast cancer cells by silencing ABC transporter genes with nanoparticle-facilitated delivery of target siRNAs

References

• MoulderSHortobagyiGNAdvances in the treatment of breast cancerClin Pharmacol Ther2008831263618091763
   PubMed Web of Science ®Google Scholar
• EstevaFJValeroVPusztaiLBoehnke-MichaudLBuzdarAUHortobagyiGNChemotherapy of metastatic breast cancer: what to expect in 2001 and beyondOncologist20016213314611306725
   PubMed Web of Science ®Google Scholar
• HortobagyiGNTreatment of breast cancerN Engl J Med1998339189749849753714
   PubMed Web of Science ®Google Scholar
• Tubiana-HulinMHow to maximize the efficacy of taxanes in breast cancerCancer Treat Rev200531Suppl 4S3916360546
   PubMed Web of Science ®Google Scholar
• FisherBRedmondCWickerhamDLDoxorubicin-containing regimens for the treatment of stage II breast cancer: the National Surgical Adjuvant Breast and Bowel Project experienceJ Clin Oncol1989755725822651576
   PubMed Web of Science ®Google Scholar
• NabholtzJMFalksonCCamposDDocetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trialJ Clin Oncol2003211096897512637459
   PubMed Web of Science ®Google Scholar
• HendersonICBerryDADemetriGDImproved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancerJ Clin Oncol200321697698312637460
   PubMed Web of Science ®Google Scholar
• BurgerHFoekensJALookMPRNA expression of breast cancer resistance protein, lung resistance related protein, multi-drug resistance gene-1 in breast cancer: correlation with chemotherapeutic responseClin Cancer Res20039282783612576456
   PubMed Web of Science ®Google Scholar
• ModokSMellorHRCallaghanRModulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancerCurr Opin Pharmacol20066435035416690355
   PubMed Web of Science ®Google Scholar
• AmbudkarSVDeySHrycynaCARamachandraMPastanIGottesmanMMBiochemical, cellular, and pharmacological aspects of the multidrug transporterAnnu Rev Pharmacol Toxicol19993936139810331089
   PubMed Web of Science ®Google Scholar
• SzakácsGPatersonJKLudwigJABooth-GentheCGottesmanMMTargeting multidrug resistance in cancerNat Rev Drug Discov201053219230
   Web of Science ®Google Scholar
• JulianoRLLingVA surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutantsBiochem Biophys Acta19764551152162990323
   PubMed Web of Science ®Google Scholar
• TrockBJLeonessaFClarkeRMultidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significanceJ Natl Cancer Inst197789139179319214671
   PubMedGoogle Scholar
• LeonessaFClarkeRATP binding cassette transporters and drug resistance in breast cancerEndocr Relat Cancer200310437312653670
   PubMed Web of Science ®Google Scholar
• KrögerNAchterrathWHegewisch-BeckerSMrossKZanderARCurrent options in treatment of anthracycline-resistant breast cancerCancer Treat Rev199925527929110544072
   PubMed Web of Science ®Google Scholar
• TsukamotoFShibaETaguchiTImmunohistochemical detection of P-glycoprotein in breast cancer and its significance as a prognostic factorBreast Cancer19974425926311091611
   PubMedGoogle Scholar
• DoyleLAYangWAbruzzoLVA multidrug resistance transporter from human MCF-7 breast cancer cellsProc Natl Acad Sci U S A1998952615665156709861027
   PubMed Web of Science ®Google Scholar
• RobeyRWToKKPolgarOABCG2: a perspectiveAdv Drug Deliv Rev200961131319135109
   PubMed Web of Science ®Google Scholar
• NoguchiKKatayamaKMitsuhashiJSugimotoYFunctions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapyAdv Drug Deliv Rev2009611263319111841
   PubMed Web of Science ®Google Scholar
• WuCPCalcagnoAMAmbudkarSVReversal of ABC drug t ransportermediated multidrug resistance in cancer cells: evaluation of current strategiesCurr Mol Pharmacol2008119310519079736
   PubMedGoogle Scholar
• BartlettNLLumBLFisherGAPhase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistanceJ Clin Oncol19941248358428151326
   PubMed Web of Science ®Google Scholar
• BooteDJDennisIFTwentymanPRPhase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancerJ Clin Oncol19961426106188636778
   PubMed Web of Science ®Google Scholar
• GiacconeGLinnSCWelinkJA dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumorsClin Cancer Res1997311200520159815591
   PubMed Web of Science ®Google Scholar
• TiwariAKSodaniKChenZSCurrent advances in modulation of ABC transporter-mediated multidrug resistance in cancerInt J Toxicol Pharmcol Res2009116
   Google Scholar
• ShiZLiangYJChenZSReversal of MDR1/P- glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivoCancer Biol Ther200651394716319528
   PubMed Web of Science ®Google Scholar
• LiuCQureshiIADingXModulation of multidrug resistance gene (MDR-1) with antisense oligodeoxynucleotidesClin Sci (Lond)199691193988774266
   PubMed Web of Science ®Google Scholar
• AlahariSKDeLongRFisherMHDeanNMVilietPJulianoRLNovel chemically modified oligonucleotides provide potent inhibition of P-glycoprotein expressionJ Pharmacol Exp Ther199828614194289655887
   PubMed Web of Science ®Google Scholar
• StuartDDKaoGYAllenTMA novel, long-circulating, and functional liposomal formulation of antisense oligodeoxynucleotides targeted against MDR1Cancer Gene Ther20007346647510766353
   PubMed Web of Science ®Google Scholar
• KobayashiHDoraiTHollandJFOhnumaTReversal of drug sensitivity in multidrug-resistant tumor cells by an MDR1(PGY1) ribozymeCancer Res1994545127112758118816
   PubMed Web of Science ®Google Scholar
• HolmPSScanlonKJDietelMReversion of multidrug resistance in the P-glycoprotein-positive human pancreatic cell line (EPP85-181RDB) by introduction of a hammerhead ribozymeBr J Cancer19947022392437914421
   PubMed Web of Science ®Google Scholar
• GaoZFieldsJZBomanBMTumor-specific expression of anti- MDR1 ribozyme selectively restores chemosensitivity in multidrug-resistant colon-adenocarcinoma cellsInt J Cancer199982334635210399951
   PubMed Web of Science ®Google Scholar
• ChowdhuryEHStrategies for tumor-directed delivery of siRNAExpert Opin Drug Deliv20118338940121314230
   PubMed Web of Science ®Google Scholar
• WuHHaitWNYangJMSmall interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cellsCancer Res20036371515151912670898
   PubMed Web of Science ®Google Scholar
• EePLHeXRossDDBeckWTModulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interferenceMol Cancer Ther20043121577158315634651
   PubMed Web of Science ®Google Scholar
• StanislausAHossainSChuaMJFabrication and intracellular delivery of siRNA/carbonate apatite nano-composites for effective knockdown of cyclin B1 geneDrugs and Therapy Studies20111e810.4081/dts.2011.e8.
   Google Scholar
• HossainSStanislausAChuaMJCarbonate apatite-facilitated intracellularly delivered siRNA for efficient knockdown of functional genesJ Control Release2010147110110820620182
   PubMed Web of Science ®Google Scholar
• ElbashirSMHarborthJLendeckelWYalcinAWeberKTuschlTDuplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cellsNature2011411683649449811373684
   PubMed Web of Science ®Google Scholar
• HarborthJElbashirSMBechertKTuschlTWeberKIdentification of essential genes in cultured mammalian cells using small interfering RNAsJ Cell Sci2001114Pt 244557456511792820
   PubMed Web of Science ®Google Scholar
• CarmichaelJDeGraffWGGazdarAFMinnaJDMitchellJBEvaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testingCancer Res19874749369423802100
   PubMed Web of Science ®Google Scholar
• SmythMJKrasovskisESuttonVRJohnstoneRWThe drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosisProc Natl Acad Sci U S A19989512702470299618532
   PubMed Web of Science ®Google Scholar
• JohnstoneRWCretneyESmythMJP-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell deathBlood1999933107510859920858
   PubMed Web of Science ®Google Scholar
• PallisMRussellNP-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathwayBlood20009592897290410779437
   PubMed Web of Science ®Google Scholar
• XuDKangHFisherMJulianoRLStrategies for inhibition of MDR1 gene expressionMol Pharmacol200466226827515266017
   PubMed Web of Science ®Google Scholar
• CohenDYangCPHorwitzSBThe products of the mdr1a and mdr1b genes from multidrug resistant murine cells have similar degradation ratesLife Sci19904674894952304382
   PubMed Web of Science ®Google Scholar
• RichertNDAldwinLNiteckiDGottesmanMMPastanIStability and covalent modification of P-glycoprotein in multidrug-resistant KB cellsBiochemistry19882720760776132905169
   PubMed Web of Science ®Google Scholar
• AkhtarSBenterIFNonviral delivery of synthetic siRNAs in vivoJ Clin Invest2007117123623363218060020
   PubMed Web of Science ®Google Scholar